Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
He was talking about assets the company had invested huge amounts of effort in that have a massive potential, Hemogenyx dont have a cure for Monkeypox and have not spent any time or money (That I know of, I could easily be wrong) on developing one. They own a platform and with it the right to sublicence the concept to any virus. IMO that tweet applies to the platform, its potential is huge, to sell CBR as an unproven technology would be a complete failure. But selling the rights for someone to exploit as a treatment for Monkeypox? If someone else wants to take it on, take on the costs associated with development testing and the associated risk if it fails? Unless Vlad had designs on developing CBR himself for Monkeypox he absolutely should be open to licencing it straight away, and if he is confident it will work offer it with no upfront payment, milestones only if it works and share of any future profits. The more people using CBR or working with it the better the chances of seeing it in clinical trials sooner rather than later.
But again, We dont know who Vlad is talking too. We also dont know if CBR is autologous or allogeneic. Hopefully we will get more details soon but its possible that while CBR WOULD work against viruses such as Monkeypox its still not cost effective to develop. If the end CAR is an off the shelf (not patient specific) treatment that is cheap to produce and quick to replicate then it could very well be an attractive treatment for Monkeypox and as such attractive to big pharma, but if its patient specific like HEMO-CAR-T then its going to be hugely expensive and less attractive as an investment for big pharma. "CBR to program human immune cells" - KINDOF suggests its Allogeneic or “off-the-shelf”, but its not black and white.
We dont know if it is specific immune cell (NK, macrophage, B-Cell) or can they modify the CBR to program multiple immune cells. Does it modify the immune cells to then express one or more receptors such as CD36, 40 etc? Is this like CRISPR in that it modifies the DNA of the cells? Does CBR behave like a virus, something they can inject and it seeks out the cells and alters them, or do they have to draw blood, isolate the immune cells, grow and multiply them, somehow have them mutate until they express the desired receptors before injecting back into the body? HOW does CBR program cells......??
Anyway, I am out for the weekend, back on Monday. Hopefully we start getting some more details about CBR soon. When we understand how it works and is produced we will know better how big the potential.
Let's hope we dont have to remind vlad of this tweet then.
Out-licensing or sale of pre-clinical assets by a R&D #biotech company is either a sign of weakness or gross negligence of the management. It is ultimately a betrayal of the company’s investors.
HT you are looking at this with a very narrow viewpoint, your talking about CBR as if there is even the remotest chance in hell that Hemogenyx are going to take it forward on their own. Hemogenyx dont have the money, they dont have the staff and they dont have the facilities.
But thats irrelevant.
"Vlad: So in the case in the case of CPR, we have a platform that can be used to generate multiple product candidates. And obviously we cannot handle ourselves. All aspects of this technology. So most likely we will try and most likely we will find people or institutions or governments that will be interested to take over, to partner with and take away a part of that platform for a specific indication or a specific direction."
If Monkeypox starts spreading and getting more media attention then there is every chance that someone will sign with Hemogenyx to test CBR on it. Like I said, it took a few months for Eli Lilly to have a treatment for Covid-19 ready to test, there are plenty of potential partners out there, if one of them decides to take CBR to tackle Monkeypox then it wont take THEM years to get it ready to test. As to the likelihood?? Well we know big pharma are greedy and this was yesterday:
"The US government has placed an $119m order with Bavarian Nordic for the Jynneos vaccine, which is effective against both the Monkeypox virus and Smallpox, the biotech company revealed.
A further $180m is also ready and waiting to buy even more vaccines if or when it is needed, altogether enabling the country to get 13 million doses into the arms of the American people."
According to the CDC, there's no proven treatment for monkeypox specifically, but the smallpox vaccine, antivirals, and vaccinia immune globulin can be used. Hemogenyx arguably are further ahead than anyone else when it comes to a specific cure for Monkeypox. I really dont know if Hemo will find a partner for monkeypox , I am not going to even suggest they are in active talks at the moment because I have no idea.
Vlad himself has said Yes it would work against HIV however so its hardly inappropriate to mention it, but again, it needs a partner to take it forward.
HFH, you were the one that headed the subject monkeypox...why are we even talking about this...CBR is years away away let's be honest...nothing happens quick in homeland so it's completely irrelevant to start mentioning any virus...will it cure AIDS ?...the answer is who the hell knows and there is little point discussing it...so pop your turtle head back in its shell.
Pretty sure he said: "then of course it could cure Monkeypox."
The RNS says:
" the platform is, in principle, applicable to almost any form of virus."
So either RNS is lying or HFH is correct
Not one of us believes Hemogenyx have the time, money, manpower to develop CBR for Monkeypox, does not mean that CBR would not cure it. Nor does it mean that Hemogenyx wont find a partner to develop CBR for Monkeypox, NO suggestion that is going to happen, this is not a ramp suggesting there will be a licencing deal next week. It might never happen for Monkeypox. BUT its possible. Vlad was able to get into bed with Eli Lilly, Orgenesis and J&J long before they had anything even remotely ready for clinical trials.
Hemo would take years and millions to get CBR ready for clinical trials, but Eli developed Bamlanivimab for Covid-19 in 3 months and got emergency approval not long after, they sold millions of doses before it was even approved to the US government. There is an acceleration program now for Coronavirus now too:
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap
If Monkeypox gets more serious then expect to see a willingness to fast track treatments.
That does not mean CBR will ever be used to cure or prevent Monkeypox, HFH didnt say that it would and I am not saying that it will, but it COULD. Likewise it could probably cure/prevent HIV, Zika virus, Dengue, Ebola etc.....
I am not saying ANYBODY is talking to Hemo about CBR for Monkeypox, but does anyone here actually know who Vlad is speaking too? Does anybody know who this company is that granted Hemogenyx access to the BSL-3 labs to test CBR in vivo was or exactly what pathogens he has access too? Does anyone know how long it takes to produce a CBR for a new viral target? Did anyone here have even the remotest clue they had have been working on a treatment for Measles for years?
HT If you took your head out of your arse for a second you’d be able to read the prefix to my statement ‘should CBR work as expected’. Now we all know you’ve been sulking since Vlad blocked you on Twitter so be a good boy, stop throwing your toys out the pram and grow up.
Oh dear ho childish...and there is you thinking hemo can cure monkey pox lmao...all they have is in vivo discovery ....and as you should know they are a million miles from a treatment...basic stuff really..
On the other hand, if I was a new investor, I might want to research the company first....now, where would I start ????
HT Whilst that is indeed true I changed my mind and decided to post. Why you might ask? A simple answer, to drown out your incessant whining about a ****ing website. Hope that addresses your concerns.
Hereforhemo...and to think only a week ago you said.
"With that I’m going to disappear into the background again as there’s nothing more I have to say until the IND application is released. GLA"
???
Should CBR work as expected then of course it could cure Monkeypox. That’s why it’s such a paradigm shift in the treatment of viral infections, it can bait any viral infection and subsequently destroy it.